Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast CancerByunghee Yoo, Zdravka Medarova, Pamela Pantazopoulos et al.|Cancer Research|2015Cited by 76